



Licensing Executive Society International Life Sciences Committee

presents a Virtual Presentation and Panel Discussion

The current landscape in ATMP – IP, partnering, funding and more!

Date: Friday, 24 March 2023

Webinar Registration Link:

<https://lesi-org.zoom.us/meeting/register/tZwpf-2hqTMuHt17sAkCQAYB-o8uWoSBtOXI>

Time: 12:00 to 13:00 (CET)

ABOUT THE SESSION:

This webinar intends to discuss the current market in the advanced therapeutic medicinal product (ATMP) space, with a particular focus on the challenges specific to this sector, and how those impact on aspects such as due diligence, collaboration, funding and deals. These topics will be explored using case studies from two ATMP companies at different growth stages, Quell Therapeutics and NK:IO. Additional insights on access to technology, and issues on manufacturing and supply chain being provided by our speaker from the Cell and Gene Therapy Catapult, which works to support companies in this sector.

SPEAKERS:

Matthew Garner	Head of IP, Cell and Gene Therapy Catapult
Jodie Albutt	VP of IP, Quell Therapeutics
Michael Hunt	CEO of NK:IO
Kerstin Papenfuss	Director, Pharma, Deep Science Ventures
Anna Gregson	Partner, Mathys & Squire LLP

The Licensing Executives Society International is an international association having 30 national and regional member societies, each comprising of men and women who have an interest in the transfer of technology, or licensing of intellectual property rights - from technical know-how and patented inventions to software, copyright and trademarks.

ABOUT THE PANELLISTS:

Matthew Garner



Matt joined the Cell and Gene Therapy Catapult in 2018 and has been Head of IP since October 2019. In addition to coordinating the identification and protection of IP arising from CGTC's research and development activities, he also supports other functions and organisational objectives where IP may be a factor, including negotiation of collaboration or licensing agreements. CGTC is a member of the UK Bioindustry Association, Matt sits on the Intellectual Property Advisory Committee and the subcommittee on the Nagoya Protocol and Access and Benefits Sharing. A qualified UK and European patent attorney, he spent the first 10 years of his career in private practice before moving to in house roles. Prior to joining the patent profession, his academic background includes a degree in natural sciences and a PhD in cellular microbiology (focusing on mechanisms of Salmonella infectivity).

Jodie Albutt



Jodie Albutt is VP of Intellectual Property at Quell Therapeutics, a biopharmaceutical cell therapy company developing treatments for a range of autoimmune and inflammatory diseases. She has over 21 years' experience working in IP, with over 7 years inhouse experience specialising in cell and gene therapies. Jodie previously worked at The Cell and Gene Therapy Catapult as their Head of IP and

The Licensing Executives Society International is an international association having 30 national and regional member societies, each comprising of men and women who have an interest in the transfer of technology, or licensing of intellectual property rights - from technical know-how and patented inventions to software, copyright and trademarks.

qualified as a European and UK patent attorney at Dehns where she worked for 14 years. She holds a PhD in molecular biology and is Vice Chair of the Intellectual Property Advisory Committee at the Bioindustry Association. In addition to dealing with the usual aspects of IP, including patent drafting, prosecution, FTO, and contentious matters, Jodie has significant experience navigating diligence proceedings associated with collaborations, partnerships, investments and in-licensing IP.

Michael Hunt



Michael Hunt is Chief Executive Officer at NK:IO Ltd, an immunotherapy business developing NK cell-based therapies for cancer. Michael has spent most of his post-qualification career in the biotechnology industry, most recently at ReNeuron Group PLC, where, as a past CEO, he led the business and its pioneering cell therapy programmes from post-start-up stage into clinical development. Michael has served on the Board and Executive Committee of the US-based Alliance for Regenerative Medicine (ARM) and is a co-founder of ARM's European Section. He has served on a number of industry-related advisory committees, including the UK BioIndustry Association's Cell & Gene Therapy Advisory Committee and the UK Cell & Gene Therapy Catapult's Advisory Panel. Michael studied economics at University College London and qualified as a chartered accountant with Ernst & Young.

Kerstin Papenfuss



The Licensing Executives Society International is an international association having 30 national and regional member societies, each comprising of men and women who have an interest in the transfer of technology, or licensing of intellectual property rights - from technical know-how and patented inventions to software, copyright and trademarks.

Kerstin started her PhD at German Cancer Research Centre and then moved to a lab at Imperial College to work on novel treatment options within the field of tumour immunology. She since has spent almost ten years in leadership roles at impact-driven organisations advancing medicine and therapeutics, while also securing an executive MBA and a women in business award. Before joining Deep Science Ventures to develop science companies designing more effective personalised therapies, Kerstin was transforming ideas for cutting edge cell and gene therapies into investable propositions at UK's Cell and Gene Therapy Catapult.

Moderator: Anna Gregson



Anna Gregson is a partner in Mathys & Squire's life sciences team. She has a formidable background in biochemistry and biotechnology, with 15 years' experience in providing strategic IP advice relating to cell and gene therapies, vaccine technologies, antibodies, viruses and virus-like particles, siRNA technology, biomarkers and diagnostics, expression systems, recombinant protein technology and therapeutics. "Commercially savvy", Anna is recommended as a leading IP strategist in the IAM Strategy 300 Global Leaders guide. She is also noted as a key lawyer in The Legal 500, in which she is praised for being "accessible, knowledgeable" and for her "really outstanding, can-do attitude". Dr Gregson is equally happy working with experienced in-house professionals and start-ups and spin-outs with limited previous IP experience. She has significant expertise in working with university and SME clients, and is adept at balancing technical excellence, budget control, transparency and predictability to develop bespoke IP strategies to match her clients' needs.

The Licensing Executives Society International is an international association having 30 national and regional member societies, each comprising of men and women who have an interest in the transfer of technology, or licensing of intellectual property rights - from technical know-how and patented inventions to software, copyright and trademarks.